NASDAQ:ARWR

Arrowhead Pharmaceuticals (ARWR) Stock Forecast, Price & News

$27.24

+0.01 (+0.04%)

(As of 09/22/2023 ET)

Compare

Today's Range: $27.04
▼
$27.64
50-Day Range: $26.84
▼
$36.08
52-Week Range: $23.09
▼
$42.48

Volume: 595,580 shs
Average Volume: 1.01 million shs
Market Capitalization: $2.92 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $54.53

Arrowhead Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.69 Rating Score
Upside/Downside: 100.2% Upside
$54.53 Price Target
Short Interest: Bearish
6.25% of Float Sold Short
Dividend Strength: N/A
Sustainability: -2.55
Upright™ Environmental Score
News Sentiment: 0.32
Based on 9 Articles This Week
Insider Trading: Selling Shares
$2.59 M Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($1.67) to ($2.65) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.24 out of 5 stars

Medical Sector

351st out of 968 stocks

Pharmaceutical Preparations Industry

145th out of 444 stocks

4.3

Analyst's Opinion

Consensus Rating
Arrowhead Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.69, and is based on 11 buy ratings, 5 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $54.53, Arrowhead Pharmaceuticals has a forecasted upside of 100.2% from its current price of $27.24.
Amount of Analyst Coverage
Arrowhead Pharmaceuticals has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

1.0

Short Interest

Percentage of Shares Shorted
6.25% of the float of Arrowhead Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Arrowhead Pharmaceuticals has a short interest ratio ("days to cover") of 7.1.
Change versus previous month
Short interest in Arrowhead Pharmaceuticals has recently increased by 4.46%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Arrowhead Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Arrowhead Pharmaceuticals does not have a long track record of dividend growth.

3.4

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Arrowhead Pharmaceuticals has received a 39.47% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Cardiovascular siRNA medication", "RNA interference medication for cancer", and "Liver-disease medication (A05)" products. See details.
Environmental Sustainability
The Environmental Impact score for Arrowhead Pharmaceuticals is -2.55.

2.4

News and Social Media Coverage

News Sentiment
Arrowhead Pharmaceuticals has a news sentiment score of 0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.53 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 9 news articles for Arrowhead Pharmaceuticals this week, compared to 3 articles on an average week.
Search Interest
Only 6 people have searched for ARWR on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
MarketBeat Follows
2 people have added Arrowhead Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Arrowhead Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,588,802.00 in company stock.
Percentage Held by Insiders
Only 5.00% of the stock of Arrowhead Pharmaceuticals is held by insiders.
Percentage Held by Institutions
65.98% of the stock of Arrowhead Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Arrowhead Pharmaceuticals are expected to decrease in the coming year, from ($1.67) to ($2.65) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Arrowhead Pharmaceuticals is -15.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Arrowhead Pharmaceuticals is -15.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Arrowhead Pharmaceuticals has a P/B Ratio of 6.90. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in phase 2b clinical trial for the treatment of dyslipidemia; ARO-HSD, which is completed phase 1/2 clinical trial to treat liver diseases; ARO-ENaC2, which is in pre-clinical stage for the treatment of dyslipidemia cystic fibrosis; ARO-C3 that is in phase 1/2a clinical trial to reduce production of complement component 3; ARO-DUX4, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH that is in phase 1 clinical trial to treat uncontrolled gout; ARO-COV, which is in pre-clinical stage for the treatment of COVID-19; ARO-RAGE, which is in phase 1/2a clinical trial to treat muco-obstructive or inflammatory pulmonary conditions; and ARO-MMP7 that is in phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop JNJ-75220795, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.

ARWR Price History

30 days | 90 days | 365 days | Advanced Chart

ARWR Stock News Headlines

September 22, 2023 | americanbankingnews.com

Christopher Richard Anzalone Sells 57,755 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Stock

September 21, 2023 | benzinga.com

Arrowhead Pharma Chief Executive Officer Trades $1.62M In Company Stock

September 22, 2023 | Chaikin Analytics (Ad)

This Stock Could Go Up 66% or More.

Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023. Click here to get his latest buy. More here.

September 20, 2023 | americanbankingnews.com

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Coverage Initiated by Analysts at Citigroup

September 19, 2023 | msn.com

Citigroup Initiates Coverage of Arrowhead Pharmaceuticals (ARWR) with Neutral Recommendation

September 19, 2023 | americanbankingnews.com

Financial Contrast: Eupraxia Pharmaceuticals (OTCMKTS:EPRXF) & Arrowhead Pharmaceuticals (NASDAQ:ARWR)

September 12, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Arrowhead Pharmaceuticals (ARWR), Shockwave Medical (SWAV) and Gilead Sciences (GILD)

September 12, 2023 | markets.businessinsider.com

Chardan Capital Keeps Their Buy Rating on Arrowhead Pharmaceuticals (ARWR)

September 22, 2023 | Chaikin Analytics (Ad)

This Stock Could Go Up 66% or More.

Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023. Click here to get his latest buy. More here.

August 13, 2023 | finance.yahoo.com

Swelling losses haven't held back gains for Arrowhead Pharmaceuticals (NASDAQ:ARWR) shareholders since they're up 99% over 5 years

August 11, 2023 | seekingalpha.com

Arrowhead Remains Well-Positioned For RNAi-Based Therapeutic Breakthroughs

August 9, 2023 | msn.com

Cantor Fitzgerald Maintains Arrowhead Pharmaceuticals (ARWR) Overweight Recommendation

August 9, 2023 | seekingalpha.com

Arrowhead Pharmaceuticals GAAP EPS of -$0.96 misses by $0.37, revenue of $15.83M misses by $29.59M

July 22, 2023 | msn.com

TD Cowen Initiates Coverage of Arrowhead Pharmaceuticals (ARWR) with Outperform Recommendation

July 21, 2023 | msn.com

B. Riley Securities Reiterates Arrowhead Pharmaceuticals (ARWR) Buy Recommendation

July 20, 2023 | markets.businessinsider.com

B.Riley Financial Keeps Their Buy Rating on Arrowhead Pharmaceuticals (ARWR)

July 17, 2023 | marketwatch.com

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1/2 Study of ARO-DUX4

July 17, 2023 | finance.yahoo.com

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate a Phase 1/2 Study of ARO-DUX4 for Facioscapulohumeral Muscular Dystrophy

June 26, 2023 | markets.businessinsider.com

Analysts Are Bullish on Top Healthcare Stocks: Arrowhead Pharmaceuticals (ARWR), Madrigal Pharmaceuticals (MDGL)

June 24, 2023 | finance.yahoo.com

Arrowhead Presents Updated Data from Phase 2 SEQUOIA Study of Investigational RNAi Therapy Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Liver Disease

June 14, 2023 | finance.yahoo.com

Goldman Sachs Lifts S&P 500 Price Target By 12.5%; Here Are 2 High-Upside Stocks to Play the Bounce

June 10, 2023 | finance.yahoo.com

ARWR - Arrowhead Pharmaceuticals, Inc.

June 7, 2023 | markets.businessinsider.com

Robert W. Baird Sticks to Their Buy Rating for Arrowhead Pharmaceuticals (ARWR)

June 6, 2023 | msn.com

HC Wainwright & Co. Reiterates Arrowhead Pharmaceuticals (ARWR) Buy Recommendation

June 6, 2023 | seekingalpha.com

Arrowhead: Biotech Innovation On Display

June 6, 2023 | markets.businessinsider.com

H.C. Wainwright Keeps Their Buy Rating on Arrowhead Pharmaceuticals (ARWR)

June 2, 2023 | msn.com

Piper Sandler Maintains Arrowhead Pharmaceuticals (ARWR) Overweight Recommendation

See More Headlines

Receive ARWR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arrowhead Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ARWR Company Calendar

Last Earnings: 8/07/2023
Today: 9/22/2023
Fiscal Year End: 9/30/2023
Next Earnings (Estimated): 11/27/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ARWR
CUSIP: N/A
CIK: 879407
Web: www.arrowheadpharma.com
Phone: (626) 304-3400
Fax: 626-304-3401
Employees: 397
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $54.53
High Stock Price Forecast: $90.00
Low Stock Price Forecast: $27.00
Forecasted Upside/Downside: +99.2%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.69
Research Coverage: 16 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.71)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-176,060,000.00
Net Margins: -69.38%
Pretax Margin: -70.12%
Return on Equity: -42.79%
Return on Assets: -21.74%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 6.69
Quick Ratio: 6.69

Sales & Book Value

Annual Sales: $243.23 million
Price / Sales: 12.07
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.95 per share
Price / Book: 6.93

Miscellaneous

Outstanding Shares: 107,190,000
Free Float: 101,833,000
Market Cap: $2.93 billion
Optionable: Optionable
Beta: 1.00

The Best High-Yield Dividend Stocks for 2023

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

Dr. Christopher R. Anzalone Ph.D. (Age 54)
CEO, Pres & Director
Comp: $1.65M

Mr. Kenneth A. Myszkowski (Age 57)
Chief Financial Officer
Comp: $761.55k

Mr. Patrick O'Brien J.D. (Age 59)
PharmD, COO, Gen. Counsel & Sec.
Comp: $749.86k

Dr. James C. Hamilton M.D. (Age 45)
MBA, Chief of Discovery & Translational Medicine
Comp: $676.81k

Ms. Tracie Oliver
Chief Commercial Officer

Dr. Mark M. Davis Ph.D.
Founder and Founder & Director of Insert Therapeutics Inc & Calando

Dr. Vincent Anzalone CFA
Head of Investor Relations & VP

Mr. Howard Lovy
Director of Communications

Dr. Mark Seefeld (Age 69)
Head of Toxicology & VP

Dr. Javier San Martin M.D. (Age 58)
Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ARWR Stock - Frequently Asked Questions

Should I buy or sell Arrowhead Pharmaceuticals stock right now?: 16 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Arrowhead Pharmaceuticals in the last twelve months. There are currently 5 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ARWR shares.
View ARWR analyst ratings or view top-rated stocks.
What is Arrowhead Pharmaceuticals' stock price forecast for 2023?: 16 Wall Street research analysts have issued 12-month price targets for Arrowhead Pharmaceuticals' stock. Their ARWR share price forecasts range from $27.00 to $90.00. On average, they expect the company's share price to reach $54.53 in the next twelve months. This suggests a possible upside of 99.2% from the stock's current price.
View analysts price targets for ARWR or view top-rated stocks among Wall Street analysts.
How have ARWR shares performed in 2023?: Arrowhead Pharmaceuticals' stock was trading at $40.56 on January 1st, 2023. Since then, ARWR shares have decreased by 32.5% and is now trading at $27.38.
View the best growth stocks for 2023 here.
When is Arrowhead Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, November 27th 2023.
View our ARWR earnings forecast.
How were Arrowhead Pharmaceuticals' earnings last quarter?: Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) issued its quarterly earnings data on Monday, August, 7th. The biotechnology company reported ($0.96) EPS for the quarter, missing the consensus estimate of ($0.58) by $0.38. The biotechnology company had revenue of $15.83 million for the quarter, compared to analysts' expectations of $45.42 million. Arrowhead Pharmaceuticals had a negative trailing twelve-month return on equity of 42.79% and a negative net margin of 69.38%. The business's revenue for the quarter was down 51.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.68) EPS.
What ETFs hold Arrowhead Pharmaceuticals' stock?: ETFs with the largest weight of Arrowhead Pharmaceuticals (NASDAQ:ARWR) stock in their portfolio include Global X Genomics & Biotechnology ETF (GNOM), Morningstar US Small Growth (MSGR), Neuberger Berman Disrupters ETF (NBDS), WisdomTree BioRevolution Fund (WDNA), SPDR S&P Biotech ETF (XBI), Principal Healthcare Innovators ETF (BTEC), Direxion Daily S&P Biotech Bull 3x Shares (LABU) and AI Powered Equity ETF (AIEQ).

What other stocks do shareholders of Arrowhead Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Arrowhead Pharmaceuticals investors own include Bellicum Pharmaceuticals (BLCM), NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Alibaba Group (BABA), Alliance Resource Partners (ARLP), Bank of America (BAC), Tesla (TSLA), Salesforce (CRM) and Advanced Micro Devices (AMD).
What is Arrowhead Pharmaceuticals' stock symbol?: Arrowhead Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARWR."
Who are Arrowhead Pharmaceuticals' major shareholders?: Arrowhead Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (11.95%), State Street Corp (5.14%), JPMorgan Chase & Co. (2.69%), Geode Capital Management LLC (2.01%), Credit Suisse AG (1.33%) and Northern Trust Corp (1.21%). Insiders that own company stock include Adeoye Y Olukotun, Backer Marianne De, Christopher Richard Anzalone, Douglas B Given, Douglas B Given, James C Hamilton, James Hassard, Kenneth Allen Myszkowski, Martin Javier San, Mauro Ferrari, Patrick O'brien, Tracie Oliver and William D Waddill.
View institutional ownership trends.
How do I buy shares of Arrowhead Pharmaceuticals?: Shares of ARWR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Arrowhead Pharmaceuticals' stock price today?: One share of ARWR stock can currently be purchased for approximately $27.38.
How much money does Arrowhead Pharmaceuticals make?: Arrowhead Pharmaceuticals (NASDAQ:ARWR) has a market capitalization of $2.93 billion and generates $243.23 million in revenue each year. The biotechnology company earns $-176,060,000.00 in net income (profit) each year or ($1.71) on an earnings per share basis.
How many employees does Arrowhead Pharmaceuticals have?: The company employs 397 workers across the globe.
How can I contact Arrowhead Pharmaceuticals?: Arrowhead Pharmaceuticals' mailing address is 177 E. Colorado Blvd Suite 700, Pasadena CA, 91105. The official website for the company is www.arrowheadpharma.com. The biotechnology company can be reached via phone at (626) 304-3400, via email at ir@arrowheadpharma.com, or via fax at 626-304-3401.

This page (NASDAQ:ARWR) was last updated on 9/22/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial